<DOC>
	<DOCNO>NCT00003294</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug amifostine may protect normal cell side effect chemotherapy . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I trial study effectiveness combination chemotherapy consist paclitaxel plus carboplatin give amifostine filgrastim treat patient recurrent metastatic cancer .</brief_summary>
	<brief_title>Chemotherapy Given With Amifostine Filgrastim Treating Patients With Recurrent Metastatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Establish maximum tolerate dose paclitaxel carboplatin combination modulate amifostine filgrastim ( G-CSF ) patient recurrent metastatic cancer . II . Define dose limit toxicity combination patient . III . Observe antitumor responses patient treated combination . OUTLINE : This dose escalation study paclitaxel . Patients receive 10 minute infusion amifostine follow paclitaxel give intravenously 3 hour follow carboplatin give 30 minute . Filgrastim ( G-CSF ) give subcutaneously daily 10 day self administration start follow day . Treatment repeat every 28 day least 3 course unless disease progression unacceptable toxicity occurs . Patients develop dose-limiting toxicity ( DLT ) give course receive one dose level lower next subsequent course . Patients stable disease may continue treatment long benefit show . In absence DLT first 3 patient treat , subsequent cohort 3 patient receive escalate dos paclitaxel schedule . If DLT occur 1 3 patient give dose level , 3 additional patient add dose . If DLT occur 1 additional patient , dose maximum tolerate dose ( MTD ) ; DLT occur 2 patient , 3 additional patient add previous dose . If DLT occur 2 6 patient , dose consider MTD . At dose , 3 case DLT lead discontinuation recruitment dose . PROJECTED ACCRUAL : Approximately 24 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent metastatic malignant disease amenable curative surgery , radiotherapy , conventional chemotherapy , investigational therapy high priority Priority give patient lung cancer cancer tumor easily available biopsy No CNS disease unless stable post radiation PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 4,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Systolic blood pressure least 90 mm Hg No severe heart decompensation No clinically significant cardiac arrhythmia EKG No inability tolerate bradycardia Other : No active , uncontrolled infection No nonmalignant systemic disease Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immune stimulate agent Chemotherapy : At least 3 week since chemotherapy ( 6 week since nitrosourea mitomycin ) recover No prior paclitaxel carboplatin No concurrent chemotherapy Endocrine therapy : No concurrent hormone therapy Radiotherapy : At least 3 week since radiotherapy major bone marrow bear area recover Concurrent radiotherapy allow vital indication pain relief Surgery : At least 3 week since surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>